Generation of CD8 Suppressor Factor and Beta Chemokines, Induced by Xenogeneic Immunization, in the Prevention of Simian Immunodeficiency Virus Infection in Macaques

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1998 Jun 6

PMID 9560257

Citations 16

Authors

Y Wang

L Tao

E Mitchell

W M Bogers

C Doyle

C A Bravery

L A Bergmeier

C G Kelly

J L Heeney

T Lehner

Affiliations

Soon will be listed here.

Abstract

Previous xenogeneic immunization experiments in rhesus macaques with simian immunodeficiency virus (SIV) grown in human CD4(+) T cells consistently elicited protection from challenge with live SIV. However, the mechanism of protection has not been established. We present evidence that xenogeneic immunization induced significant CD8 suppressor factor, RANTES (regulated upon activation, normal T cell expressed and secreted), macrophage inflammatory protein (MIP) 1alpha, and MIP-1beta (P < 0.001 - P < 0.02). The concentrations of these increased significantly in protected as compared with infected macaques (P < 0.001). Xenogeneic stimulation in vitro also up-regulated CD8 suppressor factors (SF; P < 0.001) and the beta chemokines which were neutralized by antibodies to the 3 beta chemokines. Recombinant human RANTES, MIP-1alpha and MIP-1beta which bind to simian CCR5, suppressed SIV replication in a dose-dependent manner, with RANTES being more effective than the other two chemokines. The results suggest that immunization with SIV grown in human CD4(+) T cells induces CD8-suppressor factor, RANTES, MIP-1alpha and MIP-1beta which may block CCR5 receptors and prevent the virus from binding and fusion to CD4(+) cells.

Citing Articles

Alloantigen-based AIDS vaccine: revisiting a "rightfully" discarded promising strategy.

Shearer G, Boasso A F1000 Med Rep. 2011; 3:12.

PMID: 21876718 PMC: 3155155. DOI: 10.3410/M3-12.

Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Morner A, Jansson M, Bunnik E, Scholler J, Vaughan R, Wang Y J Virol. 2011; 85(13):6442-52.

PMID: 21490092 PMC: 3126489. DOI: 10.1128/JVI.00129-11.

Specific pathogen-free status alters immunophenotype in rhesus macaques: implications for the study of simian immunodeficiency virus.

Santos R, Lin K, Mansfield K, Wachtman L AIDS Res Hum Retroviruses. 2011; 27(10):1033-42.

PMID: 21391843 PMC: 3186704. DOI: 10.1089/AID.2010.0155.

Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies.

Lakhashe S, Thakar M, Bharucha K, Paranjape R J Virol. 2007; 82(1):428-34.

PMID: 17942547 PMC: 2224394. DOI: 10.1128/JVI.00638-07.

Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426.

Babaahmady K, Oehlmann W, Singh M, Lehner T J Virol. 2007; 81(7):3354-60.

PMID: 17251296 PMC: 1866028. DOI: 10.1128/JVI.02320-06.

References

Walker C, Moody D, Stites D, Levy J . CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986; 234(4783):1563-6. DOI: 10.1126/science.2431484. View

Farzan M, Choe H, Martin K, Marcon L, Hofmann W, Karlsson G . Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med. 1997; 186(3):405-11. PMC: 2198994. DOI: 10.1084/jem.186.3.405. View

Henderson L, Sowder R, Copeland T, Oroszlan S, Arthur L, Robey W . Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol. 1987; 61(2):629-32. PMC: 253995. DOI: 10.1128/JVI.61.2.629-632.1987. View

Desrosiers R, Wyand M, Kodama T, Ringler D, Arthur L, Sehgal P . Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989; 86(16):6353-7. PMC: 297837. DOI: 10.1073/pnas.86.16.6353. View

Murphey-Corb M, Martin L, Montelaro R, Miller M, West M, Ohkawa S . A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989; 246(4935):1293-7. DOI: 10.1126/science.2555923. View

Stott E, Chan W, Mills K, Page M, Taffs F, Cranage M . Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet. 1990; 336(8730):1538-41. DOI: 10.1016/0140-6736(90)93310-l. View

Carlson J, McGraw T, Keddie E, Yee J, Rosenthal A, Langlois A . Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990; 6(11):1239-46. DOI: 10.1089/aid.1990.6.1239. View

Le Grand R, Vaslin B, Vogt G, Roques P, Humbert M, Dormont D . AIDS vaccine developments. Nature. 1992; 355(6362):684. DOI: 10.1038/355684a0. View

Osterhaus A, de Vries P, Heeney J . AIDS vaccine developments. Nature. 1992; 355(6362):684-5. DOI: 10.1038/355684b0. View

10.

Cranage M, ASHWORTH L, Greenaway P, Murphey-Corb M, Desrosiers R . AIDS vaccine developments. Nature. 1992; 355(6362):685-6. DOI: 10.1038/355685a0. View

11.

Langlois A, Weinhold K, Matthews T, Greenberg M, Bolognesi D . The ability of certain SIV vaccines to provoke reactions against normal cells. Science. 1992; 255(5042):292-3. DOI: 10.1126/science.1549775. View

12.

Chan W, Rodgers A, Hancock R, Taffs F, KITCHIN P, Farrar G . Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med. 1992; 176(4):1203-7. PMC: 2119400. DOI: 10.1084/jem.176.4.1203. View

13.

Arthur L, Bess Jr J, Sowder 2nd R, Benveniste R, Mann D, Chermann J . Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science. 1992; 258(5090):1935-8. DOI: 10.1126/science.1470916. View

14.

Cranage M, Polyanskaya N, McBride B, Cook N, ASHWORTH L, Dennis M . Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1993; 9(1):13-22. DOI: 10.1089/aid.1993.9.13. View

15.

Heeney J, van Els C, de Vries P, ten Haaft P, Otting N, Koornstra W . Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Exp Med. 1994; 180(2):769-74. PMC: 2191582. DOI: 10.1084/jem.180.2.769. View

16.

Doyle C, Bhattacharyya U, Kent K, Stott J, Jones I . Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus. J Virol. 1995; 69(2):1256-60. PMC: 188699. DOI: 10.1128/JVI.69.2.1256-1260.1995. View

17.

Bergmeier L, Walker J, Tao L, Cranage M, Lehner T . Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus. Immunology. 1994; 83(2):213-20. PMC: 1414951. View

18.

Cocchi F, Devico A, Garzino-Demo A, Arya S, Gallo R, Lusso P . Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995; 270(5243):1811-5. DOI: 10.1126/science.270.5243.1811. View

19.

Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M . Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996; 381(6584):661-6. DOI: 10.1038/381661a0. View

20.

Dragic T, Litwin V, Allaway G, Martin S, Huang Y, Nagashima K . HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996; 381(6584):667-73. DOI: 10.1038/381667a0. View